Monte Rosa Therapeutics Inc (GLUE) stock news · rev $123.7M
Monte Rosa Therapeutics Inc (GLUE) is a biotechnology company listed on NASDAQ.
This GLUE news page leads with what Monte Rosa Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for GLUE yet. We will not pad this page with generic market recap.
Latest reported GLUE revenue for 2025-12-31 was $123.7M. Net income was -$38.6M. Revenue was up 63.5% from 2024-12-31 to 2025-12-31. GLUE currently screens at market cap $1.56B.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the GLUE stock page; for the tape open the quote page.
GLUE stock news FAQ
What are GLUE's latest revenue and net income?
Latest cached Monte Rosa Therapeutics Inc (GLUE) revenue for Dec 31, 2025 was $123.7M. Net income was -$38.6M. Statements: https://lician.com/financials/glue
How did GLUE revenue change from the prior cached period?
Cached Monte Rosa Therapeutics Inc (GLUE) revenue was up 63.5% from $75.6M (Dec 31, 2024) to $123.7M (Dec 31, 2025). Statements: https://lician.com/financials/glue
What is GLUE's market cap?
Monte Rosa Therapeutics Inc (GLUE) market cap is $1.56B on the latest cached fundamentals snapshot.
What kind of company is GLUE?
Monte Rosa Therapeutics Inc (GLUE) is a biotechnology company listed on NASDAQ.
Where is GLUE stock news listed?
Cached stock news for Monte Rosa Therapeutics Inc (GLUE) is listed at https://lician.com/news/glue. Filings: https://lician.com/sec/glue
Not investment advice.